ImaginAb and Centre for Probe Development and Commercialization (CPDC) announced they have entered into a development and manufacturing agreement for the supply of ImaginAb's clinical-phase Positron Emission Tomography (PET) imaging agent Zr-89 IAB22M2C to key global geographies. Under the terms of the agreement, CPDC will manufacture and distribute Zr-89 IAB22M2C to ImaginAb's Phase II clinical trial sites, Investigator Initiated Trial sites and to sites involved in studies being conducted in collaboration and partnership with pharmaceutical companies.
Zr-89 IAB22M2C is a clinical stage CD8 T Cell imaging agent designed to non-invasively determine changes in CD8+ T cell tumor infiltrates induced by immuno-oncological treatments. This approach has the potential to guide the development of immuno-modulatory agents as well as provide an early assessment of whether a patient responds to such a treatment.
"We are delighted to forge this agreement with CPDC. Detection and mapping of CD8 T cells is a significant unmet medical need and a potential game-changer in the treatment of cancer patients,” Martyn Coombs, CEO of ImaginAb, said. “CPDC's expertise in manufacturing will enable us to achieve scale and improve effectiveness in providing clinical doses to imaging centers and hospitals in both North America, and globally."
"We are proud to be selected by ImaginAb to work on this very compelling next-generation imaging agent. Within the burgeoning field of immuno-oncology there is a clear need for better tools such as Zr-89 IAB22M2C to potentially change the clinical management of patients with cancer,” Travis Besanger, Chief Business Officer of the CPDC, said. “We are excited to apply our skills in cGMP manufacturing and international logics to enable widespread access to Zr-89 IAB22M2C for ImaginAb and its international partners and collaborators."